Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHELLY SENDERS

Allopathic & Osteopathic Physicians Pediatrics

NPI
1629030242
CMS profile
72774
Location
SOUTH EUCLID, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$3,200.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $3,200.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHELLY SENDERS

NPI 1629030242 · CMS profile ID 72774

Allopathic & Osteopathic Physicians / Pediatrics

SOUTH EUCLID, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1629030242?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHELLY SENDERS, NPI 1629030242, CMS profile ID 72774. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1629030242?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). SHELLY SENDERS, NPI 1629030242, CMS profile ID 72774. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1629030242?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
SHELLY SENDERS, NPI 1629030242, CMS profile ID 72774, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1629030242?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $3,200.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $3,200.0012/12/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673847431 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,200.00 1
PY2021 $20.00 1
PY2024 $19.72 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $54,019.97 12
PY2025 Principal investigator $1,902,218.36 170
PY2024 Recipient $275,103.88 9
PY2024 Principal investigator $1,504,720.66 124
PY2023 Recipient $102,576.00 31
PY2023 Principal investigator $2,132,839.28 106
PY2022 Recipient $295,641.25 8
PY2022 Principal investigator $2,774,710.46 131
PY2021 Recipient $6,400.00 2
PY2021 Principal investigator $3,331,898.39 191
PY2020 Recipient $940.00 1
PY2020 Principal investigator $1,688,992.60 356
PY2019 Principal investigator $803,780.84 320

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

182 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $4,415.96 12/31/2025 Non-covered Recipient Entity
Senders Pediatrics
A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants No dispute reported 06/30/2026 1232921640
Principal investigator 1 PFIZER INC. $16,760.02 12/31/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228806752
Principal investigator 1 PFIZER INC. $5,881.14 12/31/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1228816445
Principal investigator 1 PFIZER INC. $958.10 12/31/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A PHASE 1 RANDOMIZED DOUBLEBLIND THIRDPARTYUNBLINDED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE AGAINST E COLI IN HEALTHY ADULTS No dispute reported 06/30/2026 1228816882
Principal investigator 1 PFIZER INC. $1,527.89 12/18/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228712496
Principal investigator 1 ModernaTX, Inc. $4,390.39 12/17/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252975991
Principal investigator 1 PFIZER INC. $58,897.80 12/17/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228712552
Principal investigator 1 PFIZER INC. $350.35 12/17/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228815790
Recipient SANOFI PASTEUR INC. $1,620.13 12/17/2025 Covered Recipient Physician Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1226088934
Principal investigator 1 ModernaTX, Inc. $19,540.11 12/12/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252975979
Principal investigator 1 PFIZER INC. $3,564.60 12/11/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A PHASE 1 RANDOMIZED DOUBLEBLIND THIRDPARTYUNBLINDED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE AGAINST E COLI IN HEALTHY ADULTS No dispute reported 06/30/2026 1228816008
Principal investigator 1 PFIZER INC. $350.35 12/10/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228815578
Principal investigator 1 PFIZER INC. $33,559.89 12/09/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228806758
Recipient PFIZER INC. $780.00 12/08/2025 Covered Recipient Physician RSV VACCINE PROT SUBUNIT PREF 2V CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228803969
Principal investigator 1 PFIZER INC. $222.90 12/04/2025 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228806162
Principal investigator 1 PFIZER INC. $175.50 12/04/2025 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228806661
Principal investigator 1 PFIZER INC. $1,401.40 12/03/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228815689
Principal investigator 1 ModernaTX, Inc. $17,774.38 12/01/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252976029
Principal investigator 1 PFIZER INC. $1,188.20 11/26/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A PHASE 1 RANDOMIZED DOUBLEBLIND THIRDPARTYUNBLINDED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE AGAINST E COLI IN HEALTHY ADULTS No dispute reported 06/30/2026 1228818522
Recipient SANOFI PASTEUR INC. $4,152.22 11/21/2025 Covered Recipient Physician Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1226088928
Principal investigator 1 PFIZER INC. $887.99 11/19/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1228818629
Principal investigator 1 GlaxoSmithKline, LLC. $11,235.60 11/17/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE 3A, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO DEMONSTRAT No dispute reported 06/30/2026 1192181669
Principal investigator 1 ModernaTX, Inc. $36,603.90 11/14/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252975967
Principal investigator 1 PFIZER INC. $58.50 11/14/2025 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228806099
Principal investigator 1 PFIZER INC. $74.30 11/14/2025 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228806235
Principal investigator 1 PFIZER INC. $2,953.31 11/13/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1228818760
Principal investigator 1 PFIZER INC. $117.00 11/10/2025 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228806168
Principal investigator 1 PFIZER INC. $148.60 11/10/2025 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228806229
Principal investigator 1 PFIZER INC. $4,776.20 11/05/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A PHASE 1 RANDOMIZED DOUBLEBLIND THIRDPARTYUNBLINDED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE AGAINST E COLI IN HEALTHY ADULTS No dispute reported 06/30/2026 1228818587
Principal investigator 1 PFIZER INC. $887.99 11/05/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1228818672
Principal investigator 1 PFIZER INC. $17,470.02 11/04/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1228818752
Principal investigator 1 PFIZER INC. $117.00 11/03/2025 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228806175
Principal investigator 1 PFIZER INC. $148.60 11/03/2025 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228806745
Principal investigator 1 PFIZER INC. $26,120.64 11/01/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A PHASE 1 RANDOMIZED DOUBLEBLIND THIRDPARTYUNBLINDED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE AGAINST E COLI IN HEALTHY ADULTS No dispute reported 06/30/2026 1228818620
Principal investigator 1 PFIZER INC. $1,276.08 10/29/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228825651
Principal investigator 1 PFIZER INC. $58.50 10/27/2025 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228806086
Principal investigator 1 PFIZER INC. $74.30 10/27/2025 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228806093
Principal investigator 1 ModernaTX, Inc. $17,069.78 10/24/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252976005
Recipient PFIZER INC. $780.00 10/24/2025 Covered Recipient Physician RSV VACCINE PROT SUBUNIT PREF 2V CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228804023
Recipient SANOFI PASTEUR INC. $16,111.14 10/24/2025 Covered Recipient Physician Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1226088941
Principal investigator 1 PFIZER INC. $1,279.80 10/22/2025 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228812845
Principal investigator 1 PFIZER INC. $350.35 10/22/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228826117
Principal investigator 1 PFIZER INC. $369.30 10/20/2025 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228715899
Principal investigator 1 PFIZER INC. $454.50 10/20/2025 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228716079
Principal investigator 1 PFIZER INC. $227.25 10/16/2025 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED DOUBLEBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY PREGNANT WOMEN AND THEIR INFANTS No dispute reported 06/30/2026 1228811472
Principal investigator 1 PFIZER INC. $184.65 10/16/2025 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED DOUBLEBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY PREGNANT WOMEN AND THEIR INFANTS No dispute reported 06/30/2026 1228812668
Principal investigator 1 PFIZER INC. $263.50 10/16/2025 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED DOUBLEBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY PREGNANT WOMEN AND THEIR INFANTS No dispute reported 06/30/2026 1228813052
Principal investigator 1 PFIZER INC. $14,500.00 10/11/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228825007
Principal investigator 1 PFIZER INC. $2,589.34 10/11/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228825762
Principal investigator 1 PFIZER INC. $6,706.57 10/07/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228824276
Principal investigator 1 PFIZER INC. $2,133.00 09/29/2025 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED DOUBLEBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY PREGNANT WOMEN AND THEIR INFANTS No dispute reported 06/30/2026 1228812823
Principal investigator 1 PFIZER INC. $3,493.87 09/26/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1228837893
Principal investigator 1 PFIZER INC. $700.70 09/26/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228837966
Principal investigator 1 PFIZER INC. $757.50 09/25/2025 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228813528
Principal investigator 1 PFIZER INC. $615.50 09/25/2025 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228813577
Principal investigator 1 ModernaTX, Inc. $77,720.50 09/24/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252976001
Principal investigator 1 ModernaTX, Inc. $22,447.10 09/24/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252976033
Principal investigator 1 PFIZER INC. $10,467.59 09/24/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1228837888
Principal investigator 1 PFIZER INC. $4,266.00 09/23/2025 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228715901
Principal investigator 1 PFIZER INC. $1,845.54 09/17/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228837814
Principal investigator 1 SANOFI PASTEUR INC. $2,616.32 09/17/2025 Non-covered Recipient Entity
Dr Shelly David Senders Md Inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1226099491
Recipient PFIZER INC. $3,200.00 09/15/2025 Covered Recipient Physician PNEUMOCOCCAL VACCINE CONJ 7V CRM197 CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228804016
Principal investigator 1 PFIZER INC. $5,221.71 09/11/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228837571
Principal investigator 1 Novavax Inc $12,130.00 09/04/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age No dispute reported 06/30/2026 1242921092
Principal investigator 1 PFIZER INC. $350.35 09/03/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228837618
Principal investigator 1 PFIZER INC. $1,950.23 09/03/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228837779
Recipient PFIZER INC. $3,200.00 08/29/2025 Covered Recipient Physician RSV VACCINE PROT SUBUNIT PREF 2V CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228803963
Principal investigator 1 PFIZER INC. $6,930.32 08/27/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1228842348
Principal investigator 1 PFIZER INC. $1,846.91 08/23/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228841708
Principal investigator 1 ModernaTX, Inc. $26,513.24 08/22/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252976027
Principal investigator 1 PFIZER INC. $2,920.58 08/21/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228841700
Principal investigator 1 ModernaTX, Inc. $83,337.80 08/20/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252975973
Principal investigator 1 PFIZER INC. $13,778.96 08/20/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228841857
Principal investigator 1 PFIZER INC. $5,197.74 08/20/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1228842389
Principal investigator 1 PFIZER INC. $9.40 08/18/2025 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 1 RANDOMIZED DOUBLEBLIND THIRDPARTYUNBLINDED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE AGAINST E COLI IN HEALTHY ADULTS No dispute reported 06/30/2026 1228719165
Principal investigator 1 PFIZER INC. $9.40 08/18/2025 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 1 RANDOMIZED DOUBLEBLIND THIRDPARTYUNBLINDED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE AGAINST E COLI IN HEALTHY ADULTS No dispute reported 06/30/2026 1228806474
Principal investigator 1 PFIZER INC. $587.50 08/16/2025 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 1 RANDOMIZED DOUBLEBLIND THIRDPARTYUNBLINDED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE AGAINST E COLI IN HEALTHY ADULTS No dispute reported 06/30/2026 1228719093
Principal investigator 1 PFIZER INC. $887.99 08/13/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1228841798
Principal investigator 1 PFIZER INC. $44,365.10 08/13/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228842381
Principal investigator 1 PFIZER INC. $54,216.30 08/06/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228841849
Principal investigator 1 PFIZER INC. $5,226.45 08/06/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1228842343
Principal investigator 1 PFIZER INC. $3,445.42 08/06/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228842394
Principal investigator 1 PFIZER INC. $350.35 07/30/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228846907
Principal investigator 1 PFIZER INC. $1,220.73 07/30/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1228848000
Recipient ModernaTX, Inc. $1,467.20 07/28/2025 Covered Recipient Physician A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252993566
Principal investigator 1 ModernaTX, Inc. $27,528.80 07/25/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252976009
Principal investigator 1 PFIZER INC. $1,846.91 07/25/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228846867
Principal investigator 1 PFIZER INC. $1,973.82 07/23/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228846918
Principal investigator 1 PFIZER INC. $1,775.98 07/23/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1228848016
Principal investigator 1 SANOFI PASTEUR INC. $10,225.20 07/23/2025 Non-covered Recipient Entity
Dr Shelly David Senders Md Inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1226099485
Principal investigator 1 ModernaTX, Inc. $31,982.86 07/18/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252976017
Principal investigator 1 PFIZER INC. $47,790.91 07/18/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1228848091
Principal investigator 1 PFIZER INC. $12,580.10 07/16/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228847529
Principal investigator 1 PFIZER INC. $432.90 07/10/2025 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 1 RANDOMIZED DOUBLEBLIND THIRDPARTYUNBLINDED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE AGAINST E COLI IN HEALTHY ADULTS No dispute reported 06/30/2026 1228813906
Principal investigator 1 PFIZER INC. $369.30 07/10/2025 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 1 RANDOMIZED DOUBLEBLIND THIRDPARTYUNBLINDED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE AGAINST E COLI IN HEALTHY ADULTS No dispute reported 06/30/2026 1228814492
Principal investigator 1 PFIZER INC. $369.30 07/10/2025 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 1 RANDOMIZED DOUBLEBLIND THIRDPARTYUNBLINDED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE AGAINST E COLI IN HEALTHY ADULTS No dispute reported 06/30/2026 1228814499
Principal investigator 1 PFIZER INC. $432.90 07/10/2025 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 1 RANDOMIZED DOUBLEBLIND THIRDPARTYUNBLINDED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE AGAINST E COLI IN HEALTHY ADULTS No dispute reported 06/30/2026 1228814504
Principal investigator 1 ModernaTX, Inc. $7,521.48 07/09/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252975965
Principal investigator 1 ModernaTX, Inc. $43,593.88 07/09/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252975981
Principal investigator 1 PFIZER INC. $922.77 07/09/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228847452
Principal investigator 1 PFIZER INC. $5,325.00 07/09/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228847522
Principal investigator 1 PFIZER INC. $626.60 07/02/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228847590
Principal investigator 1 PFIZER INC. $5,395.65 07/02/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228848009
Principal investigator 1 PFIZER INC. $9,230.87 07/01/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228847458
Principal investigator 1 PFIZER INC. $12,500.00 06/26/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A PHASE 1 RANDOMIZED DOUBLEBLIND THIRDPARTYUNBLINDED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A VACCINE AGAINST E COLI IN HEALTHY ADULTS No dispute reported 06/30/2026 1228845238
Principal investigator 1 PFIZER INC. $1,732.58 06/25/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1228851841
Principal investigator 1 PFIZER INC. $3,374.80 06/21/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228851762
Principal investigator 1 ModernaTX, Inc. $20,762.82 06/18/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252976007
Recipient ModernaTX, Inc. $1,467.20 06/18/2025 Covered Recipient Physician A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252993568
Principal investigator 1 PFIZER INC. $3,100.00 06/18/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228851686
Principal investigator 1 PFIZER INC. $3,465.16 06/18/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1228851749
Principal investigator 1 PFIZER INC. $3,055.78 06/04/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228851696
Principal investigator 1 PFIZER INC. $1,732.58 06/04/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1228851757
Principal investigator 1 PFIZER INC. $922.77 06/04/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228851848
Principal investigator 1 ModernaTX, Inc. $19,375.52 06/02/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252976021
Principal investigator 1 PFIZER INC. $18,827.95 05/30/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228856732
Principal investigator 1 PFIZER INC. $1,527.89 05/29/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228856720
Recipient ModernaTX, Inc. $1,834.00 05/28/2025 Covered Recipient Physician A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252993562
Principal investigator 1 ModernaTX, Inc. $18,678.30 05/23/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252975969
Principal investigator 1 ModernaTX, Inc. $30,588.54 05/21/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252975993
Principal investigator 1 PFIZER INC. $5,497.70 05/21/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228856758
Principal investigator 1 SANOFI US SERVICES INC. $952.90 05/21/2025 Non-covered Recipient Entity
Dr Shelly David Senders Md Inc
A Multi-center, Multi-national, Prospective Surveillance Study of Respiratory Syncytial Virus Disease in Infants and Toddlers 6 to < 22 Months of Age No dispute reported 06/30/2026 1226097241
Principal investigator 1 SANOFI US SERVICES INC. $3,000.00 05/16/2025 Non-covered Recipient Entity
Dr Shelly David Senders Md Inc
A Multi-center, Multi-national, Prospective Surveillance Study of Respiratory Syncytial Virus Disease in Infants and Toddlers 6 to < 22 Months of Age No dispute reported 06/30/2026 1226097234
Principal investigator 1 GlaxoSmithKline, LLC. $12,320.80 05/14/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192181666
Principal investigator 1 ModernaTX, Inc. $10,597.50 05/14/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252975971
Principal investigator 1 ModernaTX, Inc. $15,340.09 05/14/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252975977
Principal investigator 1 ModernaTX, Inc. $32,145.81 05/14/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252975995
Principal investigator 1 ModernaTX, Inc. $16,714.49 05/14/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252975999
Principal investigator 1 ModernaTX, Inc. $5,385.00 05/14/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252976011
Principal investigator 1 ModernaTX, Inc. $19,848.40 05/14/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252976013
Principal investigator 1 PFIZER INC. $1,565.11 05/14/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1228856727
Principal investigator 1 PFIZER INC. $4,331.86 05/10/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228856767
Principal investigator 1 ModernaTX, Inc. $143,385.33 05/07/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252975989
Principal investigator 1 PFIZER INC. $61.55 05/05/2025 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228814890
Principal investigator 1 PFIZER INC. $72.15 05/05/2025 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228814896
Principal investigator 1 SANOFI PASTEUR INC. $23,072.02 05/01/2025 Non-covered Recipient Entity
Dr Shelly David Senders Md Inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1226099479
Principal investigator 1 PFIZER INC. $1,527.89 04/29/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228860453
Recipient ModernaTX, Inc. $4,034.80 04/28/2025 Covered Recipient Physician A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252993564
Recipient ModernaTX, Inc. $15,373.28 04/28/2025 Covered Recipient Physician A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252993570
Principal investigator 1 PFIZER INC. $10,153.64 04/24/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228856710
Principal investigator 1 ModernaTX, Inc. $24,521.25 04/18/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252975975
Principal investigator 1 PFIZER INC. $2,079.34 04/16/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1228856703
Principal investigator 1 PFIZER INC. $2,270.32 04/15/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228860458
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 04/09/2025 Non-covered Recipient Entity
Dr Shelly David Senders Md Inc
A Multi-center, Multi-national, Prospective Surveillance Study of Respiratory Syncytial Virus Disease in Infants and Toddlers 6 to < 22 Months of Age No dispute reported 06/30/2026 1226097227
Principal investigator 1 PFIZER INC. $5,816.72 04/08/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228860315
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 04/02/2025 Non-covered Recipient Entity
Dr Shelly David Senders Md Inc
A Multi-center, Multi-national, Prospective Surveillance Study of Respiratory Syncytial Virus Disease in Infants and Toddlers 6 to < 22 Months of Age No dispute reported 06/30/2026 1226097246
Principal investigator 1 SANOFI US SERVICES INC. $5,232.50 04/02/2025 Non-covered Recipient Entity
Dr Shelly David Senders Md Inc
A Multi-center, Multi-national, Prospective Surveillance Study of Respiratory Syncytial Virus Disease in Infants and Toddlers 6 to < 22 Months of Age No dispute reported 06/30/2026 1226097252
Principal investigator 1 PFIZER INC. $3,215.16 03/29/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228861622
Principal investigator 1 PFIZER INC. $1,746.60 03/26/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1228862234
Principal investigator 1 ModernaTX, Inc. $32,048.25 03/24/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252975963
Principal investigator 1 PFIZER INC. $6,218.16 03/22/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228862201
Principal investigator 1 ModernaTX, Inc. $19,447.82 03/21/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252975983
Principal investigator 1 ModernaTX, Inc. $14,409.60 03/21/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252976023
Principal investigator 1 ModernaTX, Inc. $24,620.12 03/19/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252976025
Principal investigator 1 PFIZER INC. $5,391.05 03/19/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1228861689
Principal investigator 1 PFIZER INC. $6,357.87 03/19/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228862227
Principal investigator 1 PFIZER INC. $10,726.06 03/18/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228861616
Principal investigator 1 ModernaTX, Inc. $19,635.27 03/14/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252975985
Principal investigator 1 PFIZER INC. $17,622.54 03/14/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228861632
Principal investigator 1 PFIZER INC. $3,130.22 03/12/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1228863064
Principal investigator 1 PFIZER INC. $306.80 03/11/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228862081
Principal investigator 1 PFIZER INC. $332.74 03/05/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1228862221
Principal investigator 1 ModernaTX, Inc. $17,190.03 02/26/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252976003
Principal investigator 1 PFIZER INC. $5,209.56 02/26/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1228837807
Principal investigator 1 PFIZER INC. $18,785.23 02/21/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1228837975
Principal investigator 1 SANOFI PASTEUR INC. $14,522.36 02/19/2025 Non-covered Recipient Entity
Dr Shelly David Senders Md Inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1226099475
Principal investigator 1 ModernaTX, Inc. $76,956.75 02/14/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252975997
Principal investigator 1 Merck Sharp & Dohme LLC $2,500.00 02/10/2025 Non-covered Recipient Entity
Senders Pediatrics
A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants No dispute reported 06/30/2026 1232921638
Principal investigator 1 PFIZER INC. $9,998.19 02/08/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228837971
Principal investigator 1 ModernaTX, Inc. $84,572.80 02/07/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252975987
Principal investigator 1 PFIZER INC. $1,746.60 02/07/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1228837899
Principal investigator 1 ModernaTX, Inc. $8,500.00 02/05/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252976015
Principal investigator 1 ModernaTX, Inc. $2,587.00 02/05/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252976019
Principal investigator 1 PFIZER INC. $306.80 02/05/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228837577
Principal investigator 1 PFIZER INC. $5,435.10 02/05/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228837820
Principal investigator 1 ModernaTX, Inc. $43,187.49 02/03/2025 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252976031
Principal investigator 1 PFIZER INC. $306.80 01/29/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228863797
Principal investigator 1 PFIZER INC. $1,227.20 01/22/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228863148
Principal investigator 1 PFIZER INC. $15,473.52 01/22/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 1228863760
Principal investigator 1 PFIZER INC. $10,881.78 01/09/2025 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228863939
Principal investigator 1 PFIZER INC. $2,717.55 01/01/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228863155
Principal investigator 1 PFIZER INC. $920.40 01/01/2025 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1228863752